Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study-Reference-Cited by-同舟云学术

Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study

Published:2021-02-03 Issue:8 Volume:32 Page:1601-1608
ISSN:0937-941X
Container-title:Osteoporosis International
language:en
Short-container-title:Osteoporos Int

Author:

McCloskey E. V.^ORCID,Johansson H.,Harvey N. C.,Lorentzon M.,Shi Y.,Kanis J. A.

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00198-020-05815-0.pdf

Reference28 articles.

1. McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420

2. Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26

3. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543

4. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427

5. Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A (2018) FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33:1219–1226

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on fracture risk assessment in osteoporosis;Current Opinion in Endocrinology, Diabetes & Obesity;2024-05-30

2. Sclerostin inhibitor (SERM): Romosozumab;Diagnosis and Treatment of Osteoporosis;2024

3. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study;Journal of Bone and Mineral Metabolism;2023-12-12

4. An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis;Journal of Endocrinological Investigation;2023-10-24

5. Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part I);SurgiColl;2023-09-22